NASDAQ:SWAV - Nasdaq - US82489T1043 - Common Stock - Currency: USD
SHOCKWAVE MEDICAL INC
NASDAQ:SWAV (5/30/2024, 8:19:22 PM)
After market: 334.8 +0.05 (+0.01%)334.75
-0.08 (-0.02%)
The current stock price of SWAV is 334.75 USD. In the past month the price increased by 1.49%. In the past year, price increased by 15.77%.
/PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced...
We also talk with Sean Milliken, managing director of The Motley Fool Foundation’s ImpactFool (IF) Fund.
Looking beyond the headlines creates an opportunity for investors who have the patience to seek must-own overlooked stocks.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.
Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.64 | 223.92B | ||
ISRG | INTUITIVE SURGICAL INC | 79.08 | 206.46B | ||
BSX | BOSTON SCIENTIFIC CORP | 43.87 | 152.60B | ||
SYK | STRYKER CORP | 32.19 | 149.59B | ||
MDT | MEDTRONIC PLC | 17.33 | 116.65B | ||
BDX | BECTON DICKINSON AND CO | 18.42 | 70.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.72 | 42.07B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.6 | 39.72B | ||
IDXX | IDEXX LABORATORIES INC | 41.34 | 38.08B | ||
RMD | RESMED INC | 27.2 | 35.30B | ||
DXCM | DEXCOM INC | 51.45 | 34.16B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.23 | 25.29B |
Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company is headquartered in Santa Clara, California and currently employs 1,001 full-time employees. The company went IPO on 2019-03-07. The firm is focused on development and commercialization of products intended to transform the way calcified cardiovascular disease is treated. The company provides care for the treatment of calcified cardiovascular disease through its differentiated local delivery of sonic pressure waves, intravascular lithotripsy (IVL). Its Shockwave M5 IVL catheter and Shockwave M5+ IVL catheter are five-emitter catheters for use in its IVL System in medium-diameter vessels for the treatment of peripheral artery disease (PAD). Its Shockwave S4 IVL catheter is a four-emitter catheter for use in its IVL System in small-diameter vessels for the treatment of PAD. Its Shockwave L6 IVL catheter is a six-emitter catheter for use in its IVL System in large diameter vessels for the treatment of PAD. Its Shockwave C2 IVL catheter and Shockwave C2+ IVL catheter are two-emitter catheters for use in its IVL System for the treatment of coronary artery disease (CAD).
SHOCKWAVE MEDICAL INC
5403 Betsy Ross Dr
Santa Clara CALIFORNIA 95054 US
CEO: Douglas Godshall
Employees: 1001
Company Website: https://shockwavemedical.com/
Phone: 15102794262
The current stock price of SWAV is 334.75 USD.
The exchange symbol of SHOCKWAVE MEDICAL INC is SWAV and it is listed on the Nasdaq exchange.
SWAV stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for SWAV, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of SWAV.
SWAV does not pay a dividend.
SWAV will report earnings on 2024-08-05, after the market close.
The PE ratio for SWAV is 78.21. This is based on the reported non-GAAP earnings per share of 4.28 and the current share price of 334.75 USD.
ChartMill assigns a technical rating of 9 / 10 to SWAV. When comparing the yearly performance of all stocks, SWAV is one of the better performing stocks in the market, outperforming 87.72% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to SWAV. SWAV has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months SWAV reported a non-GAAP Earnings per Share(EPS) of 4.28. The EPS increased by 12.34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 20.76% | ||
ROA | 9.95% | ||
ROE | 21.76% | ||
Debt/Equity | 0.97 |
ChartMill assigns a Buy % Consensus number of 54% to SWAV. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 36.11% and a revenue growth 27.69% for SWAV